RxDoctor Payments Data

Latoya Perry, MD

Gynecologic Oncology · South Bend, INNPI 1629255880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 35.4% of the total. 2025 is the largest year on record at $339, more than ten times the $27 reported in 2020. That places this record below the midpoint for gynecologic oncology clinicians in IN, where the typical reported total is $1,688.

$557in general payments, 2019–2025

Across 14 payments — averaging $39.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$197
  • Tempus AI, Inc$179
  • AstraZeneca$117
  • Johnson & Johnson$24
  • Merck$20
  • AbbVie$16
  • plus $3 from 1 others
$1,643,831in research payments, 2019–2025

Across 103 payments — averaging $15,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tesaro, Inc.$1M
  • GSK$522K
  • E.r. Squibb & Sons, L.L.C.$87K
  • Mirati Therapeutics, Inc.$18K

What the payments were for

  • Food & beverage$55499%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$557 in reported general payments places this provider in the 20th percentile of 26 gynecologic oncology providers in Indiana.

See all gynecologic oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$78,764
Medicare patients
133
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib25$273,054
Ondansetron Hcl52$554
Dexamethasone32$539
Olanzapine25$252
Prochlorperazine Maleate22$234
Nystatin12$103
Lorazepam14$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$117$273,05425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 26 gynecologic oncology providers in Indiana.

Other gynecologic oncology in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →